Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain).
BACKGROUND
There is little available data regarding the epidemiology of herpes zoster (HZ) in Spain. This study's main goal was to estimate the annual incidence of HZ in the Autonomous Community of Valencia.


METHODS
From December 1st 2006 to December 1st 2007, a prospective study was carried out in 24 primary health care centres that together provide care for a population of 36,030 persons aged >14 years. We included all adult patients with a clinical diagnosis of HZ who were seen at these centres during the one-year study period. Demographic (i.e., age, gender, and area of residence) and clinical data were also collected from these patients.


RESULTS
A total of 146 cases of HZ were identified during the study period. The annual incidence of HZ was 4.1/1,000 individuals >14 years of age (95% confidence interval [CI]: 3.4-4.7). Cases of HZ were predominantly unilateral and most commonly affected women and people living in rural areas. The most frequently reported symptoms were pain, dysesthesia and itching. A total of 46% of patients also had underlying illnesses (e.g., chronic diseases and/or malignancy) and 24% of patients experienced complications, which were mostly ocular in nature. A total of 91% of patients were treated with antiviral drugs. The median time from symptoms onset to diagnosis was 6.3 days (range: 2.0-8.3).


CONCLUSIONS
HZ is a common illness in our region (especially in the older population) that causes a significant clinical burden on primary care providers.
Cebrián-Cuenca
Ana M
AM
Centro Superior de Investigaciones en Salud Pública de Valencia (CSISP), Av, Cataluña 21, 46020, Valencia, Spain.
Díez-Domingo
Javier
J
Rodríguez
María San-Martín
MS
Puig-Barberá
Joan
J
Navarro-Pérez
Jorge
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006562:Herpes Zoster / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011153:Population; D011320:Primary Health Care; D013030:Spain / Q000453:epidemiology; D055815:Young Adult
D000998:Antiviral Agents
Mayo Clin Proc. 2007 Nov;82(11):1341-9
17976353
J Infect. 2002 Nov;45(4):233-6
12423610
Medicine (Baltimore). 1982 Sep;61(5):310-6
6981045
Vaccine. 2006 Feb 27;24(9):1308-14
16352376
Am J Public Health. 2010 Jun;100(6):1116-22
20075320
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006866
19370655
Clin Infect Dis. 2007 Jan 1;44 Suppl 1:S1-26
17143845
Surg Oncol. 2010 Sep;19(3):149-54
20056406
Epidemiol Infect. 2001 Oct;127(2):305-14
11693508
Epidemiol Infect. 2009 Jan;137(1):38-47
18466661
J Infect Dis. 2005 Jun 15;191(12):2002-7
15897984
Vaccine. 2006 May 1;24(18):3946-52
16564115
Proc R Soc Med. 1965 Jan;58:9-20
14267505
J Pain. 2004 Aug;5(6):344-56
15336639
Clin Infect Dis. 2001 Jul 1;33(1):62-9
11389496
J Fam Pract. 2000 Mar;49(3):255-64
10735485
Clin Microbiol Rev. 2010 Jan;23(1):202-17
20065330
Lancet. 2002 Aug 31;360(9334):678-82
12241874
Ann Epidemiol. 2006 Sep;16(9):692-5
16516488
Arch Intern Med. 1995 Aug 7-21;155(15):1605-9
7618983
J Gen Intern Med. 2005 Aug;20(8):748-53
16050886
Pediatrics. 1999 Jul;104(1 Pt 1):1-6
10390252
An Sist Sanit Navar. 2008 Jan-Apr;31(1):71-80
18496581
N Engl J Med. 2002 Aug 1;347(5):340-6
12151472
Epidemiol Infect. 2005 Apr;133(2):245-53
15816149
BMC Public Health. 2005 Jun 16;5:68
15960856
Epidemiol Infect. 2004 Jan;132(1):1-5
14979582
N Engl J Med. 2005 Jun 2;352(22):2271-84
15930418
Clin Infect Dis. 2001 May 15;32(10):1481-6
11317250
Epidemiol Infect. 2000 Dec;125(3):651-69
11218215
BMC Infect Dis. 2007 Jun 15;7:59
17570859
Lancet Infect Dis. 2004 Jan;4(1):26-33
14720565